CA2307624A1 - Cellules souches hematopoietiques - Google Patents

Cellules souches hematopoietiques Download PDF

Info

Publication number
CA2307624A1
CA2307624A1 CA 2307624 CA2307624A CA2307624A1 CA 2307624 A1 CA2307624 A1 CA 2307624A1 CA 2307624 CA2307624 CA 2307624 CA 2307624 A CA2307624 A CA 2307624A CA 2307624 A1 CA2307624 A1 CA 2307624A1
Authority
CA
Canada
Prior art keywords
cells
lin
stem cells
human
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2307624
Other languages
English (en)
Inventor
John E. Dick
Dominique Bonnet
Mickie Bhatia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Original Assignee
Hsc Research And Development Limited Partnership
John E. Dick
Dominique Bonnet
Mickie Bhatia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Research And Development Limited Partnership, John E. Dick, Dominique Bonnet, Mickie Bhatia filed Critical Hsc Research And Development Limited Partnership
Priority to CA 2307624 priority Critical patent/CA2307624A1/fr
Publication of CA2307624A1 publication Critical patent/CA2307624A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des cellules souches hématopoïétiques humaines appelées CD34-Lin- et CD34-CD38-Lin- et des procédés d'isolement et d'utilisation de ces cellules dans des compositions et dans des méthodes de reconstitution d'une population cellulaire déficiente ou absente. La présente invention concerne également une population de cellules souches hématopoïétiques humaines pouvant être isolées et modifiées génétiquement et destinées à être introduites chez un patient humain, afin de corriger divers dysfonctionnements génétiques, mises en culture et encore différenciées in vitro pour obtenir une nouvelle population de cellules.
CA 2307624 1997-10-31 1998-10-30 Cellules souches hematopoietiques Abandoned CA2307624A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2307624 CA2307624A1 (fr) 1997-10-31 1998-10-30 Cellules souches hematopoietiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,219,869 1997-10-31
CA002219869A CA2219869A1 (fr) 1997-10-31 1997-10-31 Cellule de souche humaine cd-34 hematopoietique
PCT/CA1998/001012 WO1999023205A1 (fr) 1997-10-31 1998-10-30 Cellules souches hematopoietiques
CA 2307624 CA2307624A1 (fr) 1997-10-31 1998-10-30 Cellules souches hematopoietiques

Publications (1)

Publication Number Publication Date
CA2307624A1 true CA2307624A1 (fr) 1999-05-14

Family

ID=4161713

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002219869A Abandoned CA2219869A1 (fr) 1997-10-31 1997-10-31 Cellule de souche humaine cd-34 hematopoietique
CA 2307624 Abandoned CA2307624A1 (fr) 1997-10-31 1998-10-30 Cellules souches hematopoietiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002219869A Abandoned CA2219869A1 (fr) 1997-10-31 1997-10-31 Cellule de souche humaine cd-34 hematopoietique

Country Status (3)

Country Link
AU (1) AU9732098A (fr)
CA (2) CA2219869A1 (fr)
WO (1) WO1999023205A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
WO2002039109A2 (fr) * 2000-11-07 2002-05-16 British Columbia Cancer Agency Procede de detection de cellules hematopoietiques humaines capables de reconstitution a court terme
EP2292734A1 (fr) 2001-12-07 2011-03-09 Geron Corporation Cellules hématopoïétiques à partir de cellules souches embryonnaires humaines
US7799324B2 (en) 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
EP1694345A1 (fr) 2003-12-04 2006-08-30 Regents Of The University Of Minnesota Compositions et methodes de traitement des maladies lysosomales
EP2087101A2 (fr) 2006-11-24 2009-08-12 Regents of the University of Minnesota Cellules progénitrices endothermiques
EP2746770A1 (fr) * 2012-12-21 2014-06-25 Stembios Technologies, Inc. Procédé pour évaluer l'effet d'action sur un sujet basé sur des dynamiques cellulaires de tiges
AU2014338555B2 (en) 2013-10-24 2019-10-10 Fondazione Telethon Method
JP2021527397A (ja) * 2018-06-07 2021-10-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 造血幹細胞を生成するための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039489A1 (fr) * 1995-06-06 1996-12-12 Whitehead Institute For Biomedical Research Isolation de cellules souches hematopoïetiques de mammaliennes

Also Published As

Publication number Publication date
AU9732098A (en) 1999-05-24
WO1999023205A1 (fr) 1999-05-14
CA2219869A1 (fr) 1999-04-30

Similar Documents

Publication Publication Date Title
US5665557A (en) Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
US7416887B2 (en) Methods for use of MPL ligands with primitive human stem cells
JP2002516085A (ja) 哺乳動物における造血幹細胞集団に影響を及ぼす組成物および使用法
CN102781449A (zh) 增强自然杀伤细胞增殖和活性的方法
AU2006321172B2 (en) Methods of improving stem cell homing and engraftment
Chute et al. A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures
WO2008041370A1 (fr) Structure renfermant des cellules progénitrices hématopoïétiques issues de cellules es et procédé de préparation de cellules sanguines faisant appel à ladite structure
TW202003837A (zh) 表現趨化因子受體及細胞接著分子之cd3陰性細胞之集團、及其用途及其製造方法
CA2307624A1 (fr) Cellules souches hematopoietiques
JPH06508528A (ja) インビトロ由来ヒト好中球前駆体細胞
CA2391657A1 (fr) Composition de cellules souches traitees a l'anti-tgf-beta, et procede correspondant
JPH10136978A (ja) 造血幹細胞の培養方法
AU782937B2 (en) Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same
US20020098521A1 (en) Method and marker for the isolation of human multipotent hematopoietic stem cells
Rowley et al. Hematopoietic precursors resistant to treatment with 4-hydroperoxycyclophosphamide: requirement for an interaction with marrow stroma in addition to hematopoietic growth factors for maximal generation of colony-forming activity
Greinix et al. Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules
Holyoake et al. The CD34 antigen: potential clinical advantages of CD34 selection
EP1673445B1 (fr) Produits sanguins issus de cellules souches mesenchymateuses
WO1999000486A1 (fr) Compositions et procedes permettant d'induire la croissance et la differenciation de cellules souches hematopietiques
Muench et al. In vitro development of megakaryocytes and platelets
Greinix et al. Specific growth inhibition of primitive hematopoietic progenitor cells
Summers Identification, isolation and ex vivo expansion of haemopoietic progenitor and stem cells
Su Ex vivo expansion of hematopoietic stem and progenitor cells from umbilical cord blood: Cytokine combinations, platelet-derived growth factor and stromal cell support
Brandt Self-renewal of human bone marrow-derived hematopoietic stem cells in vitro
Holyoake Investigation of the Effects of In Vitro Cytokine Exposure on Short and Long Term Reconstituting Haemopoietic Stem and Progenitor Cells in a Murine Model

Legal Events

Date Code Title Description
FZDE Discontinued